- $1.91bn
- $1.49bn
- $255.87m
Schrödinger stops development of blood cancer therapy after two patient deaths
Schrodinger falls after ending blood cancer therapy development on patient deaths
Brief: Schrödinger Discontinues Development Of Sgr-2921 Cdc7 Inhibitor
Schrodinger Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Schrodinger Q2 Software Revenue USD 40.5 Million
Schrodinger Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Schrödinger Gets Fast Track Status for SGR-1505 in Relapsed/Refractory Waldenström Macroglobulinemia Treatment
Brief: Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) To Newly Appointed Chief Commercial Officer
Brief: Schrödinger Expands Executive Leadership Team With Appointment Of Mannix Aklian As Chief Commercial Officer
Brief: Schrödinger Announces CFO Appointment
Brief: Schrodinger Inc Says Schrödinger Restructures Operations To Reduce Workforce And Costs - SEC Filing
Schrodinger Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Schrödinger’S Statement Regarding FDA Plan To Phase Out Animal Testing Requirement For Monoclonal Antibodies And Other Drugs
U.S. STOCKS ON THE MOVE-Wells Fargo, American Express, Mondelez
U.S. STOCKS ON THE MOVE-TreeHouse Foods, Sarepta Therapeutics, Walmart
U.S. STOCKS ON THE MOVE-Morgan Stanley, Fluence Energy, Bank of New York
AI-based drug developers rise on US FDA's plans to replace animal testing
Schrodinger Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Schrodinger Q4 Software Gross Margin 83%